Lidocaine (Topical)

Pharmacologic Category

Analgesic, Topical; Local Anesthetic

Dosing: Adult

Anesthesia, topical:

Cream:

LidaMantle, Lidovex: Skin irritation: Apply a thin film to affected area 2 to 3 times daily as needed

LMX 4: Skin irritation: Apply up to 3 to 4 times daily to intact skin

LMX 5: Relief of anorectal pain and itching: Apply to affected area up to 6 times daily

Gel: Apply to affected area ≤4 times daily as needed (maximum dose: 4.5 mg/kg, not to exceed 300 mg)

Intradermal injection: Apply one intradermal lidocaine (0.5 mg) device to the site planned for venipuncture, 1 to 3 minutes prior to needle insertion.

Jelly: Maximum dose: 30 mL (600 mg) in any 12-hour period:

Anesthesia of male urethra: 5 to 30 mL (100 to 600 mg)

Anesthesia of female urethra: 3 to 5 mL (60 to 100 mg)

Lotion: Apply a thin film to affected area 2 or 3 times daily.

Ointment: Apply as a single application not exceeding 5 g of ointment (equivalent to lidocaine base 250 mg); maximum: 20 g of ointment/day (equivalent to lidocaine base 1,000 mg/day).

Oral topical solution (2% viscous):

Anesthesia of the mouth: 15 mL swished in the mouth and spit out no more frequently than every 3 hours (maximum: 4.5 mg/kg [or 300 mg per dose]; 8 doses per 24-hour period)

Anesthesia of the pharynx: 15 mL gargled no more frequently than every 3 hours (maximum: 4.5 mg/kg [or 300 mg per dose]; 8 doses per 24-hour period); may be swallowed

Oral topical solution (4%): Note: For use in mucous membranes of oral and nasal cavities and proximal GI tract. Apply 1 to 5 mL (40 to 200 mg) to affected area (maximum dose: 4.5 mg/kg, not to exceed 300 mg per dose)

Oral topical endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]:

Nasal: 20 to 60 mg (maximum dose: 500 mg for procedure <1 minute or 600 mg for procedure >5 minutes)

Oropharyngeal: 20 to 200 mg (maximum dose: 500 mg for procedure <1 minute or 600 mg for procedure >5 minutes)

Respiratory tract: 50 to 400 mg (maximum dose: 400 mg for procedure <1 minute or 600 mg for procedure >5 minutes)

Trachea, larynx, bronchi: 50 to 200 mg (maximum dose: 200 mg for procedure <1 minute or 400 mg for procedure >5 minutes)

Patch: Note: One ZTlido 1.8% patch provides equivalent lidocaine exposure to one Lidoderm 5% patch.

Lidoderm, ZTlido: Postherpetic neuralgia: Apply patch to most painful area. Up to 3 patches may be applied in a single application. Patch(es) may remain in place for up to 12 hours in any 24-hour period.

OTC 4%: Pain (localized): Apply patch to painful area. Patch may remain in place for up to 12 hours in any 24-hour period. No more than 1 patch should be used in a 24-hour period.

Topical solution (OTC 4% [products labeled for external use only]): Apply thin layer to affected area every 6 to 8 hours; maximum of 3 applications in 24 hours

Dosing: Geriatric

Refer to adult dosing. Administer reduced doses commensurate with age and physical status.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use caution in patients with severe hepatic disease.

Dosing: Pediatric

Note: Smaller areas of treatment are recommended in younger or smaller patients (<12 months or <10 kg) or those with impaired elimination (Fein 2012); use lowest effective dose

Anesthetic: Topical: Dose varies with age, weight, and physical condition.

Cream:

Lidovex (lidocaine 3.75%), Lidocaine 4.12%: Infants, Children, and Adolescents: Apply a thin film to affected area 2 to 3 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

LMX 4 (lidocaine 4%, liposomal): Children >2 years and Adolescents: Apply a thin film to affected area up to 3 to 4 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

Gel: Children ≥2 years and Adolescents: Apply to affected area up to 3 to 4 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

Jelly: Children and Adolescents: Dose varies with age and weight; maximum dose: 4.5 mg/kg/dose; not to exceed 600 mg in a 12-hour period

Lotion: Children and Adolescents: Apply to affected area up to 2 to 3 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

Ointment: Children and Adolescents: Apply to affected area; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose

Patch: OTC 4%: Children ≥12 years and Adolescents: Apply patch to painful area. Patch may remain in place for up to 12 hours. No more than 1 patch should be used in a 24-hour period.

Minor dermal procedures (eg, peripheral IV cannulation, venipuncture, lumbar puncture, abscess drainage, joint aspiration); anesthetic: Limited data available:

Intradermal injection: Zingo: Venipuncture or peripheral IV catheter insertion: Children ≥3 years and Adolescents: Apply one intradermal lidocaine (0.5 mg) device to the site planned for venipuncture, administer 1 to 3 minutes prior to the IV needle insertion; perform procedure within 10 minutes of application

Topical: Cream LMX 4 (lidocaine 4%):

Infants and Children <4 years: Apply 1 g of cream to site 30 minutes prior to procedure (Fein 2012; Taddio 2005)

Children ≥4 years and Adolescents ≤17 years: Apply 1 to 2.5 g of cream to site 30 minutes prior to procedure (Eichenfield 2002; Fein 2012; Koh 2004; Luhmann 2004; Taddio 2005)

Note: For peripheral IV cannulation, some have recommended application to 6.25 cm2 of skin (Sobanko 2012).

Oral inflammation or irritation: Topical: Note: Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects, including fatalities, have been reported; AAP, AAPD, and ISMP strongly discourage use (AAP 2011; AAPD 2012; ISMP 2014).

Oral solution (2% viscous): Dose should be adjusted according to patient's age, weight, and physical condition:

Infants and Children <3 years: 24 mg/dose (1.2 mL) applied to area with a cotton-tipped applicator no more frequently than every 3 hours; maximum dose: 4 doses per 12-hour period; should not be swallowed

Children ≥3 years and Adolescents: Do not exceed 4.5 mg/kg/dose; maximum dose: 300 mg/dose; swished in the mouth and spit out no more frequently than every 3 hours; maximum dose: 4 doses per 12-hour period

Topical solution (4%): Note: For use on mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract; use lowest effective dose. Children and Adolescents: Do not exceed 4.5 mg/kg/dose; maximum dose: 300 mg/dose; applied with cotton applicator, cotton pack, or via spray; should not be swallowed

Topical endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: Children 2 to <12 years: Topical: Dose varies with age, weight, and application site.

Maximum dose:

Laryngotracheal: 3 mg/kg/dose

Nasal/oropharyngeal: 4 to 5 mg/kg/dose

Rectal pain, itching: Topical:

Cream: LMX 5 (lidocaine 5%): Children ≥12 years and Adolescents: Apply to affected area up to 6 times daily

Gel: Topicaine (lidocaine 5%): Children ≥12 years and Adolescents: Apply to affected area up to 6 times daily

Skin irritation: Topical: Cream: LMX 4 (lidocaine 4%): Children ≥2 years and Adolescents: Apply up to 3 to 4 times daily to intact skin

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with severe renal impairment; accumulation of active metabolites may occur with long-term treatment.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use caution in patients with severe hepatic disease.

Use: Labeled Indications

Intradermal injection (Zingo): Topical local analgesia prior to venipuncture or peripheral IV cannulation in children ≥3 years of age; topical local analgesia prior to venipuncture in adults.

Jelly: Prevention and control of pain in procedures involving the male and female urethra; for topical treatment of painful urethritis

Oral topical solution (2% viscous): Topical anesthesia of irritated or inflamed oral mucous membranes and pharyngeal tissue; reducing gagging during the taking of x-ray. Note: Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects have been reported (AAP 2011; AAPD 2012; ISMP 2014).

Oral topical solution (4%): Topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. Note: Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects have been reported (AAP 2011; AAPD 2012; ISMP 2014).

Oral topical solution (metered-dose spray) [Canadian product]: Topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.

Patch (Lidoderm, ZTlido): Relief of pain associated with postherpetic neuralgia

Patch (OTC 4%): Temporary relief of minor localized pain

Rectal: Temporary relief of pain and itching due to anorectal disorders

Topical: Local anesthetic for mucous membrane of the oropharynx; lubricant for intubation; use in laser/cosmetic surgeries; pruritus, pruritic eczemas, insect bites, pain, soreness, minor burns (including sunburns), cuts, and abrasions of the skin; discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes

Class and Related Monographs

Local Anesthetics, Topical

Clinical Practice Guidelines

Diabetic Neuropathy:

Neurology, "Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy," April 2011

Oral Health Care:

AAP, Oral Health Initiative, January 2011

American Academy of Pediatric Dentistry, Infant Oral Health, 2012

Pain Management

AAP, Relief of Pain and Anxiety in Pediatric Patients in Emergency Medical Systems, November 2012

Administration: Topical

Gel (Topicaine): Apply a moderately thick layer to affected area (~1/8 inch thick). Allow time for numbness to develop (~20 to 60 minutes after application). When used prior to laser surgery, avoid mucous membranes and remove prior to laser treatment.

Intradermal injection: Refer to manufacturer's labeling for administration technique. Apply intradermal lidocaine 1 to 3 minutes prior to needle insertion; perform procedure within 10 minutes following application. Application of one additional intradermal lidocaine at a new location is acceptable after a failed attempt at venous access; multiple administrations of intradermal lidocaine at the same location are not recommended. Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier. When removing the device from the pouch, be careful not to touch the purple outlet (open end) to avoid contamination; do not use if the device has been dropped or the pouch is damaged or torn.

Ointment: Use of a sterile gauze is suggested for application to broken skin; apply to tube prior to intubation. In dentistry, apply to previously dried oral mucosa; subsequent removal of excess saliva with cotton rolls or saliva ejector minimizes dilution of ointment, permits maximum penetration, and minimizes possibility of swallowing the ointment. For use with the insertion of new dentures, apply to all denture surfaces contacting mucosa.

Oral topical solution (2% viscous): Mouth irritation or inflammation: Have patient swish medication around mouth and then spit it out. In children <3 years, apply to affected area with cotton-tipped applicator (do not use to relieve teething pain). Do not eat or chew gum for 60 minutes following use. For pharyngeal anesthesia, patient should gargle and may swallow medication. Do not eat or chew gum for 60 minutes following use.

Oral topical endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: Attach nozzle and prime pump 5 to 10 times prior to first use; prime ~2 times (to remove air) when switching to a new nozzle. Product should be in upright position while spraying. Do not modify manufacturer supplied nozzle. Discard nozzle after use (do not reuse). Do not use on cuffs or endotracheal tubes made of plastic (may damage cuff).

Patch:

Lidoderm: Apply to most painful area of skin immediately after removal from protective envelope. Do not apply to non-intact skin. May be cut (with scissors, prior to removal of release liner) to appropriate size. Clothing may be worn over application area. After removal from skin, fold used patches so the adhesive side sticks to itself; avoid contact with eyes. Remove immediately if irritation or a burning sensation occurs. Wash hands after application. Avoid contact with water (eg, bathing, swimming, showering). Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). Discard any used or unused patches by folding adhesive sides together and dispose of in trash away from children and pets.

ZTlido: Apply to most painful area of skin immediately after removal from protective envelope. Do not apply to non-intact skin. May be cut (with scissors, prior to removal of release liner) to appropriate size. Clothing may be worn over application area. After removal from skin, fold used patches so the adhesive side sticks to itself; avoid contact with eyes. Remove immediately if irritation or a burning sensation occurs. Wash hands after application. Avoid contact with water (eg, bathing, swimming, showering). Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). May be used during moderate exercise (eg, biking for 30 minutes). Discard any used or unused patches by folding adhesive sides together and dispose of in trash away from children and pets. Throw away any patch that comes off and will not stick to skin; a new patch can be applied for a total duration of 12 hours of used and new patch together.

OTC 4%: Remove protective film and apply to painful area. Avoid contact with eyes or mucous membranes. Wash hands after application. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). Discard any used or unused patches by folding adhesive sides together and dispose of in trash away from children and pets.

Administration: Pediatric

Topical:

Cream, gel: Apply to affected area.

LMX-4: Minor dermal procedure (peripheral IV cannulation, venipuncture): Infants and Children: Apply to skin at least 30 minutes before procedure; in most trials, occlusion of the application site was used (Koh 2004; Luhmann 2004; Taddio 2005) while another trial showed that occlusion was not required (Eichenfield 2002); however, occlusion of the site may be helpful in active infants and children to hold cream in place

Intradermal injection device (eg, Zingo): Refer to manufacturer's labeling for administration technique. Apply intradermal lidocaine 1 to 3 minutes prior to needle insertion; perform procedure within 10 minutes following application. Application of one additional intradermal lidocaine at a new location is acceptable after a failed attempt at peripheral IV cannulation; multiple administrations of intradermal lidocaine at the same location are not recommended. Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier. When removing the device from the pouch, be careful not to touch the purple outlet (open end) to avoid contamination; do not use if the device has been dropped or the pouch is damaged or torn.

Ointment: Use of a sterile gauze is suggested for application to broken skin; apply to tube prior to intubation. In dentistry, apply to previously dried oral mucosa; subsequent removal of excess saliva with cotton rolls or saliva ejector minimizes dilution of ointment, permits maximum penetration, and minimizes possibility of swallowing the ointment. For use with the insertion of new dentures, apply to all denture surfaces contacting mucosa.

Oral solution (2% viscous): Do not eat or chew gum for 60 minutes following use.

Mouth irritation or inflammation: Have patient swish medication around mouth and then spit it out. In children <3 years, apply small amount to affected area with cotton-tipped applicator (do not use to relieve teething pain).

Pharyngeal anesthesia: Patient should gargle and may swallow medication. In children <3 years, apply to affected area with cotton-tipped applicator.

Rectal gel: Children ≥12 years and Adolescents: If possible, clean affected area with mild soap and water and blot dry prior to application.

Topical patch:

OTC 4%: Children ≥12 years and Adolescents: Remove protective film and apply to painful area. Avoid contact with eyes or mucous membranes. Wash hands after application. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). Discard any used or unused patches by folding adhesive sides together and dispose of in trash away from children and pets.

Topical oral endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: Attach nozzle and prime pump by actuating 5 to 10 times prior to first use; actuate ~2 times (to remove air) when switching to a new nozzle. Product should be in upright position while spraying. Do not modify manufacturer supplied nozzle. Discard nozzle after use (do not reuse). Do not use on cuffs or endotracheal tubes made of plastic (may damage cuff).

Storage/Stability

All formulations: Store at room temperature; see product-specific labeling for any additional storage requirements. Store and dispose of products out of the reach of children and pets.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to stop pain.

• It is used to treat painful nerve diseases.

• It is used to treat signs of hemorrhoids or rectal irritation.

• It is used to ease long-term pain problems.

• It is used to ease pain from skin irritations.

• It is used to ease pain caused by shingles.

• It is used to treat mouth sores.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Redness

• Edema

• Skin discoloration

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Infection

• Acidosis like confusion, fast breathing, fast heartbeat, abnormal heartbeat, severe abdominal pain, nausea, vomiting, fatigue, shortness of breath, or loss of strength and energy.

• Methemoglobinemia like blue or gray color of the lips, nails, or skin; abnormal heartbeat; seizures; severe dizziness or passing out; severe headache; fatigue; loss of strength and energy; or shortness of breath.

• Difficulty breathing

• Slow breathing

• Shallow breathing

• Severe application site irritation

• Severe numbness or tingling

• Rectal bleeding

• Rectal pain

• Seizures

• Lightheadedness

• Fatigue

• Blurred vision

• Confusion

• Vision changes

• Anxiety

• Dizziness

• Passing out

• Noise or ringing in the ears

• Nausea

• Vomiting

• Sensation of warmth

• Sensation of cold

• Tremors

• Twitching

• Chest pain

• Slow heartbeat

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Contraindications

Hypersensitivity to lidocaine or any component of the formulation; hypersensitivity to another local anesthetic of the amide type; traumatized mucosa, bacterial infection at the site of application (lotion and Lidovex only).

Warnings/Precautions

Concerns related to adverse effects:

• Familial malignant hyperthermia: Many drugs used during the conduct of anesthesia may trigger familial malignant hyperthermia; not known whether amide-type local anesthetics trigger this reaction. However, standard protocol for management should be available. Early unexplained signs of tachycardia, tachypnea, labile blood pressure, and metabolic acidosis may precede temperature elevation. If familial malignant hyperthermia is confirmed, discontinue triggering agent and initiate appropriate therapy (eg, oxygen, dantrolene) and other supportive measures.

• Hypersensitivity: Use with caution in patients with known drug sensitivities. Allergic reactions (cutaneous lesions, urticaria, edema, or anaphylactoid reactions) may be a result of sensitivity to lidocaine (rare) or preservatives used in formulations. Patients allergic to para-aminobenzoic acid (PABA) derivatives (eg, procaine, tetracaine, benzocaine) have not shown cross sensitivity to lidocaine.

• Local effects: Irritation, sensitivity and/or infection may occur at the site of application; discontinue use and institute appropriate therapy if local effects occur. Mild and transient application site reactions may occur during or immediately after treatment with patch; spontaneously resolves within a few minutes to hours; may include blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechial, pruritus, vesicles, or the area may be the locus of abnormal sensation.

• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants <6 months are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).

• Systemic adverse effects: Potentially life-threatening side effects (eg, irregular heartbeat, seizures, coma, respiratory depression, death) have occurred when used prior to cosmetic procedures. Excessive dosing for any indication (eg, application to large areas, use above recommended dose, application to denuded or inflamed skin, or wearing of device for longer than recommended), smaller patients, and/or impaired elimination may lead to increased absorption and systemic toxicity; patient should adhere strictly to recommended dosage and administration guidelines; serious adverse effects may require the use of supportive care and resuscitative equipment; lidocaine toxicity may occur at blood concentrations above 5 mcg/mL.

Disease-related concerns:

• Bleeding tendencies/platelet disorders: Intradermal injection: Use with caution; may have a higher risk of superficial dermal bleeding.

• Cardiovascular disease: Use with caution in patients with severe shock or heart block.

• Dermal integrity reduced: Application to broken or inflamed skin may lead to increased systemic absorption; use caution.

• Familial malignant hyperthermia: May potentially trigger malignant hyperthermia; follow standard protocol for identification and treatment.

• Hepatic impairment: Use caution in patients with severe hepatic disease due to diminished ability to metabolize systemically-absorbed lidocaine.

• Pseudocholinesterase deficiency: Use with caution; these patients have a greater risk of developing toxic plasma concentrations of lidocaine.

• Sepsis/severely traumatized mucosa: Use with extreme caution in the presence of sepsis and/or severely traumatized mucosa due to an increased risk of rapid systemic absorption at application site.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

• Intradermal injection: Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

• Topical cream, liquid, lotion, gel, and ointment: Do not leave on large body areas for >2 hours. Not for ophthalmic use. Some products are not recommended for use on mucous membranes; consult specific product labeling.

• Topical oral solution: When used in mouth or throat, topical anesthesia may impair swallowing and increase aspiration risk. Avoid food for ≥60 minutes following oral or throat application. This is especially important in the pediatric population. Numbness may increase the danger of tongue/buccal biting trauma; ingesting food or chewing gum should be avoided while mouth or throat is anesthetized. Excessive doses or frequent application may result in high plasma levels and serious adverse effects; strictly adhere to dosing instructions. Use measuring devices to measure the correct volume, if applicable, to ensure accuracy of dose.

• Topical patch: Apply only on intact skin. Do not use around or in the eyes. To avoid accidental ingestion by children, store and dispose of products out of the reach of children. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub).

Special populations:

• Acutely ill patients: Use with caution; acutely ill patients should be given reduced doses commensurate with their age and physical status.

• Elderly and debilitated patients: Use with caution; elderly and debilitated patients should be given reduced doses commensurate with their age and physical status.

• Oral topical solution/viscous: [US Boxed Warning]: Life-threatening and fatal events in infants and young children: Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients <3 years of age have been reported with use of lidocaine 2% viscous solution when it was not administered in strict adherence to the dosing and administration recommendations. Lidocaine 2% viscous solution should generally not be used for teething pain. For other conditions, the use of lidocaine 2% viscous solution in patients <3 years of age should be limited to those situations where safer alternatives are not available or have been tried but failed. To decrease the risk of serious adverse events, instruct caregivers to strictly adhere to the prescribed dose and frequency of administration, and store the prescription bottle safely out of reach of children. Multiple cases of seizures (including fatalities) have occurred in pediatric patients using viscous lidocaine for oral discomfort, including use for teething pain and stomatitis (Curtis 2009; Giard 1983; Gonzalez del Ray 1994; Hess 1988; Mofenson 1983; Puczynski 1985; Rothstein 1982; Smith 1992). The FDA recommends against using topical OTC medications for teething pain as some products may cause harm. The American Academy of Pediatrics (AAP) recommends managing teething pain with a chilled (not frozen) teething ring or gently rubbing/massaging with the caregiver's finger. Use of topical anesthetics for teething is discouraged by the AAP, the American Academy of Pediatric Dentistry, and the ISMP (AAP 2012; AAPD 2012; ISMP 2014).

• Pediatric: Use with caution; children should be given reduced doses commensurate with their age and physical status.

Other warnings/precautions:

• Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heartbeats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to cover the skin following application.

Geriatric Considerations

Instruct patient or caregiver on appropriate use of topical lidocaine products.

Warnings: Additional Pediatric Considerations

In infants and children, seizures (some fatal) have been reported following topical lidocaine ingestion at serum concentrations within the therapeutic range of 1 to 5 mcg/mL (Curtis 2009); others have reported toxic effects with excessive doses or frequent application of topical oral lidocaine solution that resulted in high plasma concentrations. Multiple cases of seizures, including fatalities, have occurred in pediatric patients using viscous lidocaine for oral discomfort (eg, teething pain, herpetic gingivostomatitis) (Curtis 2009; Giard 1983; Gonzalez del Rey 1994; Hess 1988; Mofenson 1983; Puczynski 1985; Rothstein 1982; Smith 1992). Lidocaine oral solution is not approved for treatment of teething pain or discomfort; off-label use is strongly discouraged and should be avoided. When used for oral irritation, the solution should not be swallowed, but should be applied topically with a cotton swab to individual lesions or the excess should be expectorated (swish and spit). Toxicology data suggests that in infants and children<6 years, ingestion of as little as 5 mL of lidocaine may result in serious toxicity and emergency care should be sought (Curtis 2009). Additionally, the FDA recommends against using topical OTC medications for teething pain as some products may cause harm; the use of OTC topical anesthetics (eg, benzocaine) for teething pain is also discouraged by AAP, and The American Academy of Pediatric Dentistry (AAP 2011; AAPD 2012). The AAP recommends managing teething pain with a chilled (not frozen) teething ring or gently rubbing/massaging with the caregiver's finger.

Topical patches (both used and unused) may cause toxicities in children; used patches still contain large amounts of lidocaine; store and dispose patches out of the reach of children; efficacy of patches in pediatric patients has not been evaluated due to safety concerns.

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Pregnancy Risk Factor

B

Pregnancy Considerations

Adverse events were not observed in animal reproduction studies using the systemic injection. Lidocaine and its metabolites cross the placenta and can be detected in the fetal circulation following injection (Cavalli 2004; Mitani 1987). The amount of lidocaine absorbed topically (and therefore available systemically to potentially reach the fetus) varies by dose administered, duration of exposure, and site of application. Cumulative exposure from all routes of administration should be considered.

Breast-Feeding Considerations

Information regarding the presence of lidocaine in breast milk following topical administration has not been located. Lidocaine is present in breast milk following systemic administration (Dryden 2000; Giuliani 2001; Lebedevs 1993; Ortega 1999; Zeisler 1986). However, the oral bioavailability is low and rapid biotransformation occurs via the liver. The amount of lidocaine to reach the bloodstream of a breastfed infant is expected to be low and would be unlikely to cause adverse effects (Dryden 2000; Giuliani 2001; Lebedevs 1993; Ortega 1999).

Lidocaine is considered compatible with breastfeeding (WHO 2002). The manufacturer recommends caution be used when administering topical lidocaine to breastfeeding women. Cumulative exposure from all routes of administration should be considered.

Briggs' Drugs in Pregnancy & Lactation

• Lidocaine

Adverse Reactions

Adverse effects vary with formulation and extent of systemic absorption; children may be at increased risk.

>10%:

Dermatologic: Erythema (intradermal powder: adults - 67%; children & adolescents - 53%)

Hematologic & oncologic: Petechia (intradermal powder: 44% to 46%)

1% to 10%:

Cardiovascular: Edema (intradermal powder: 4% to 8%)

Dermatologic: Pruritus (intradermal powder: 9%; also occurs with topical patch)

Gastrointestinal: Nausea (intradermal powder: 2%; also occurs with topical patch), vomiting

Frequency not defined:

Cardiovascular: Bradycardia, circulatory shock, flushing (topical patch), hypotension, shock

Central nervous system: Apprehension, central nervous system depression, confusion, disorientation (topical patch), dizziness, drowsiness, euphoria, excitement, headache (topical patch), hyperesthesia (topical patch), hypoesthesia (topical patch), localized warm feeling, loss of consciousness, metallic taste (topical patch), nervousness, numbness, pain (exacerbation; topical patch), paresthesia, seizure, sensation disorder (topical patch), sensation of cold, twitching

Dermatologic: Dermatitis, exfoliation of skin (topical patch), papule (topical patch), skin blister (topical patch), skin depigmentation (topical patch), skin edema (topical patch), skin erosion (topical patch), urticaria

Gastrointestinal: Dysgeusia (topical patch)

Hematologic & oncologic: Bruise (topical patch), methemoglobinemia

Hypersensitivity: Anaphylactoid shock, angioedema, hypersensitivity reaction

Local: Application site burning (topical patch), application site erythema (topical patch), application site vesicles (topical patch), local discoloration (topical patch), local irritation (topical patch)

Neuromuscular & skeletal: Asthenia, laryngospasm, tremor

Ophthalmic: Blurred vision, diplopia

Otic: Tinnitus

Respiratory: Bronchospasm, dyspnea, respiratory depression

Allergy and Idiosyncratic Reactions

• Aniline Dye Allergy
• Local Anesthetic Hypersensitivity/Allergy

Toxicology

• Local Anesthetics

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions Open Interactions

Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone. Risk C: Monitor therapy

Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Beta-Blockers: May increase the serum concentration of Lidocaine (Topical). Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). Risk D: Consider therapy modification

Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Risk C: Monitor therapy

Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine. Risk C: Monitor therapy

Duvelisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Fosnetupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Larotrectinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy

Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy

MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus. Risk D: Consider therapy modification

Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Risk C: Monitor therapy

Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Any CYP3A4 substrate used with stiripentol requires closer monitoring. Risk D: Consider therapy modification

Genes of Interest

• Cytochrome P450 1A2
• Cytochrome P450 3A4
• G6PD - Lidocaine
• P-Glycoprotein

Advanced Practitioners Physical Assessment/Monitoring

Assess for signs of systemic toxicity. Assess skin for signs of hypersensitivity

Nursing Physical Assessment/Monitoring

Educate the patient on importance of proper topical administration. Instruct patient to report any signs of systemic toxicity (irregular heartbeat, seizures, respiratory distress). Instruct patient to report any severe skin irritation.

Dosage Forms Considerations

EnovaRX-Lidocaine, and Lidtopic Max creams are compounded from kits. Refer to manufacturer’s package insert for compounding instructions.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Cream, External:

AneCream: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

AneCream5: 5% (15 g, 30 g [DSC]) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

LC-4 Lidocaine: 4% (45 g [DSC]) [contains cetyl alcohol]

LC-5 Lidocaine: 5% (45 g) [contains cetyl alcohol]

Lidotral: 3.88% (85 g) [contains cetearyl alcohol, methylparaben, propylene glycol, propylparaben]

Lidovex: 3.75% (60 g [DSC]) [contains cetyl alcohol, methylparaben, propylparaben]

Lidovin: 3.95% (60 g [DSC]) [contains peg-40 castor oil]

Lidozol: 3.75% (60 g [DSC]) [contains peg-40 castor oil]

Lipocaine 5: 5% (30 g, 113 g) [fragrance free, mineral oil free, no artificial color(s), paraben free; contains cetyl alcohol]

LMX 4: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol]

LMX 5: 5% (15 g, 30 g) [contains benzyl alcohol]

RectaSmoothe: 5% (30 g) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben]

RectiCare: 5% (15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

Generic: 3.88% (85 g [DSC]); 4% (5 g, 15 g, 30 g, 120 g); 5% (15 g, 28.35 g, 30 g)

Cream, External, as hydrochloride:

CidalEaze: 3% (453.6 g [DSC]) [contains aluminum sulfate, calcium acetate, cetyl alcohol, methylparaben, propylparaben]

Lidocaine Plus: 4% (120 g) [contains cetearyl alcohol, propylene glycol, trolamine (triethanolamine)]

Lidopin: 3% (28 g, 85 g); 3.25% (28 g, 85 g) [contains cetyl alcohol, methylparaben, propylparaben]

NeuroMed7: 4% (63 g) [contains propylene glycol, trolamine (triethanolamine)]

Pain Relieving: 4% (15 g, 30 g [DSC]) [contains cetearyl alcohol, disodium edta]

Predator: 4% (63 g) [contains propylene glycol, trolamine (triethanolamine)]

Xolido: 2% (118 mL) [contains methylisothiazolinone]

Xolido XP: 4% (118 mL) [contains methylisothiazolinone]

Generic: 3% (28.3 g, 28.35 g, 85 g); 4% (120 g); 4.12% (28.3 g, 85 g)

Gel, External:

Lubricaine: 4% (113 g); 5% (113 g) [estrogen free, fragrance free, no artificial color(s), no artificial flavor(s), paraben free, soy free, sugar free; contains benzyl alcohol]

Topicaine: 4% (10 g, 30 g, 113 g) [contains benzyl alcohol, disodium edta]

Topicaine 5: 5% (10 g, 30 g, 113 g) [contains benzyl alcohol, disodium edta]

Gel, External, as hydrochloride:

Alocane Emergency Burn Max Str: 4% (75 mL)

Astero: 4% (30 mL [DSC], 90 mL)

LDO Plus: 4% (30 mL)

LidoDose: 3% (1 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]

LidoDose Pediatric Bulk Pack: 3% (1 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]

LidoRx: 3% (10 mL, 30 mL, 90 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]

Lidotrex: 2% (28.33 g) [contains trolamine (triethanolamine)]

7T Lido: 2% (85 g) [contains trolamine (triethanolamine)]

Tranzarel: 4% (120 mL [DSC]) [contains disodium edta, menthol, methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]

Generic: 2% (5 mL, 30 mL)

Jet-injector, Intradermal, as hydrochloride:

Zingo: 0.5 mg (1 ea [DSC])

Jet-injector, Intradermal, as hydrochloride [preservative free]:

Zingo: 0.5 mg (1 ea)

Generic: 0.5 mg (1 ea)

Kit, External:

AneCream: 4% [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]

Lidopac: 5% [contains polyethylene glycol]

LidoPure Patch: 5% [contains edetate disodium, methylparaben, propylene glycol, propylparaben]

Lidotrans 5 Pak: 5% [DSC] [contains polyethylene glycol]

LMX 4 Plus: 4% [contains benzyl alcohol]

Xryliderm: 5% [DSC] [contains edetate disodium, methylparaben, propylene glycol, propylparaben]

Zeyocaine: 5% [DSC]

Generic: 4%

Kit, External, as hydrochloride:

Venipuncture Px1 Phlebotomy: 2% [latex free; contains methylparaben, propylparaben]

Liquid, External, as hydrochloride:

LevigoSP: 2.5% (150 mL) [paraben free; contains propylene glycol]

Lotion, External:

Gen7T: 3.5% (120 g) [contains edetate disodium, trolamine (triethanolamine)]

Lotion, External, as hydrochloride:

Anastia: 2.75% (15 g [DSC]) [contains cetyl alcohol, methylparaben, propylparaben]

Eha: 4% (88 mL) [contains methylisothiazolinone]

Lido-K: 3% (177 mL [DSC]) [contains cetyl alcohol, methylparaben, propylparaben]

Lido-Sorb: 3% (177 mL) [contains cetyl alcohol, edetate disodium, methylparaben, propylparaben]

Lidozion: 3% (177 mL) [contains cetyl alcohol, edetate disodium, methylparaben, propylparaben]

Numbonex: 2.75% (30 g [DSC]) [contains cetyl alcohol, methylparaben, propylparaben]

Zionodil: 3% (177 mL) [contains cetyl alcohol, edetate disodium, methylparaben, propylparaben]

Zionodil 100: 3% (177 mL) [contains cetyl alcohol, propylene glycol, trolamine (triethanolamine)]

Generic: 3% (118 mL [DSC], 177 mL)

Ointment, External:

Lidocaine PAK: 5% (30 g [DSC]) [contains polyethylene glycol, propylene glycol]

Premium Lidocaine: 5% (50 g)

Generic: 5% (30 g, 35.44 g, 50 g, 150 g [DSC], 250 g [DSC], 2500 g)

Patch, External:

First Care Pain Relief: 4% (5 ea) [odor free, paraben free]

Gen7T: 3.5% (15 ea) [contains propylene glycol]

Lido King: 4% (5 ea) [contains edetate disodium, methylparaben, propylene glycol, propylparaben]

Lidocaine Pain Relief: 4% (5 ea) [contains methylparaben, polysorbate 80, propylene glycol, propylparaben]

Lidoderm: 5% (1 ea, 30 ea) [contains disodium edta, methylparaben, propylene glycol, propylparaben]

Pain Relief Maximum Strength: 4% (5 ea) [contains methylparaben, polysorbate 80, propylene glycol, propylparaben]

Re-Lieved Maximum Strength: 4% (6 ea) [odor free]

ZTlido: 1.8% (1 ea, 30 ea)

Generic: 4% (10 ea); 5% (1 ea, 15 ea, 30 ea)

Prefilled Syringe, External, as hydrochloride:

Generic: 2% (20 mL)

Prefilled Syringe, External, as hydrochloride [preservative free]:

Glydo: 2% (6 mL, 11 mL) [pvc free]

Generic: 2% (5 mL, 10 mL)

Solution, External, as hydrochloride:

Xylocaine: 4% (50 mL [DSC]) [contains methylparaben]

Generic: 4% (50 mL)

Solution, Mouth/Throat, as hydrochloride:

Generic: 2% (15 mL, 100 mL)

Solution, Mouth/Throat, as hydrochloride [preservative free]:

Generic: 4% (4 mL)

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Gel, External, as hydrochloride:

Lidodan: 2% (10 mL)

Xylocaine: 2% (30 mL) [contains methylparaben, propylparaben]

Ointment, External:

Lidodan: 5% (15 g, 30 g, 35 g)

Xylocaine: 5% (35 g) [contains polyethylene glycol, propylene glycol]

Prefilled Syringe, External, as hydrochloride:

Jelido: 2% (6 mL, 11 mL)

Xylocaine: 2% (10 mL)

Generic: 2% (12.5 g, 12.5 mL)

Anatomic Therapeutic Chemical (ATC) Classification

• C05AD01
• D04AB01

Generic Available (US)

Yes

Pricing: US

Cream (AneCream External)

4% (per gram): $1.28

Cream (AneCream5 External)

5% (per gram): $1.60

Cream (Lidocaine (Anorectal) External)

5% (per gram): $0.56

Cream (Lidocaine External)

4% (per gram): $1.28 - $2.07

5% (per gram): $0.52 - $1.97

Cream (Lidocaine HCl External)

3% (per gram): $1.44 - $2.06

4% (per gram): $3.75

4.12% (per gram): $23.32

Cream (Lidotral External)

3.88% (per gram): $17.63

Cream (Lipocaine 5 External)

5% (per gram): $0.72

Cream (LMX 4 External)

4% (per gram): $1.68

Cream (LMX 5 External)

5% (per gram): $2.20

Cream (NeuroMed7 External)

4% (per gram): $2.86

Cream (RectaSmoothe External)

5% (per gram): $0.64

Cream (RectiCare External)

5% (per gram): $1.01

Gel (7T Lido External)

2% (per gram): $11.14

Gel (Alocane Emergency Burn Max Str External)

4% (per mL): $0.09

Gel (Astero External)

4% (per mL): $11.53

Gel (LDO Plus External)

4% (per mL): $13.29

Gel (Lidocaine HCl Urethral/Mucosal External)

2% (per mL): $1.68

Gel (LidoDose External)

3% (per mL): $3.50

Gel (LidoDose Pediatric Bulk Pack External)

3% (per mL): $3.50

Gel (Lidotrex External)

2% (per gram): $65.65

Gel (Lubricaine External)

4% (per gram): $0.30

5% (per gram): $0.30

Gel (Topicaine 5 External)

5% (per gram): $0.65

Gel (Topicaine External)

4% (per gram): $1.05

Jet-injector (Lidocaine HCl Intradermal)

0.5 mg (per each): $197.70

Jet-injector (Zingo Intradermal)

0.5 mg (per each): $365.30

Kit (AneCream External)

4% (per each): $33.00

Kit (Lidocaine-Transparent Dressing External)

4% (per each): $30.00 - $59.00

Kit (LidoPure Patch External)

5% (per each): $23.44

Kit (LMX 4 Plus External)

4% (per each): $48.07

Kit (Venipuncture Px1 Phlebotomy External)

2% (per each): $981.00

Liquid (Dologesic Pain Relief Roll-On External)

4% (per mL): $0.13

Lotion (Lido-Sorb External)

3% (per mL): $13.87

Lotion (Lidocaine HCl External)

3% (per mL): $0.40 - $14.10

Lotion (Lidozion External)

3% (per mL): $16.75

Ointment (Lidocaine External)

5% (per gram): $1.75 - $10.38

Patch (First Care Pain Relief External)

4% (per each): $46.00

Patch (Lido King External)

4% (per each): $1.18

Patch (Lidocaine External)

4% (per each): $46.00

5% (per each): $9.36 - $49.80

Patch (Lidoderm External)

5% (per each): $23.96

Patch (Re-Lieved Maximum Strength External)

4% (per each): $5.47

Patch (ZTlido External)

1.8% (per each): $11.40

Prefilled Syringe (Glydo External)

2% (per mL): $1.19

Solution (Lidocaine HCl External)

4% (per mL): $0.96 - $1.29

Solution (Lidocaine HCl Mouth/Throat)

4% (per mL): $7.50

Solution (Lidocaine Viscous HCl Mouth/Throat)

2% (per mL): $0.07 - $0.08

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction

Pharmacodynamics/Kinetics

Onset: Intradermal injection: 1 to 3 minutes; Topical: 3 to 5 minutes; Transdermal: ~4 hours (Davies 2004)

Duration: Intradermal injection: 10 minutes

Absorption: Transdermal (5%): 3% ± 2% (following application of 3 patches), extent and rate variable; dependent upon concentration, dose, application site, and duration of exposure

Protein binding: 60% to 80%

Metabolism: Hepatic via CYP1A2 (major) and CYP3A4 (minor); active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX)

Half-life, elimination: IV: 1.5 to 2 hours; prolonged 2-fold or more in hepatic impairment

Time to peak: Transdermal (5%): 11 hours (following application of 3 patches); Transdermal (1.8%): ~14 hours (following application of 3 patches)

Excretion: Urine (<10% as unchanged drug)

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: Accumulation of metabolites may occur.

Dental Use

Topical local anesthetic

Patch: Production of mild topical anesthesia of accessible mucous membranes of the mouth prior to superficial dental procedures

Oral topical solution (viscous): Reduce gagging during dental impressions and x-rays

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Metallic taste.

Effects on Bleeding

No information available to require special precautions

Dental Usual Dosing

Anesthesia, topical:

Oral topical solution (viscous): Note: Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects have been reported; AAP, AAPD, and ISMP strongly discourage use (AAP 2011; AAPD 2012; ISMP 2014).

Infants and Children <3 years: ≤1.2 mL applied to area with a cotton-tipped applicator no more frequently than every 3 hours (maximum: 4 doses per 12-hour period); use only if the underlying condition requires treatment with product volume of ≤1.2 mL)

Children ≥3 years and Adolescents: Should not exceed 4.5mg/kg/dose (or 300mg/dose); swished in the mouth and spit out no more frequently than every 3 hours (maximum: 4 doses per 12-hour period)

Adults: Anesthesia of the mouth: 15 mL swished in the mouth and spit out no more frequently than every 3 hours (maximum: 8 doses per 24-hour period)

Postherpetic neuralgia: Adults: Patch: Apply patch to most painful area. Up to 3 patches may be applied in a single application. Patch may remain in place for up to 12 hours in any 24-hour period.

Index Terms

Lidocaine HCl; Lidocaine Hydrochloride; Lidocaine Patch; Lignocaine Hydrochloride; Viscous Lidocaine; Xylocaine Viscous; Zingo; ZTlido

FDA Approval Date

November 30, 1948

References

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319.[PubMed 11487763]

Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.[PubMed 3960626]

Alocane (lidocaine) [prescribing information]. Pleasant Prairie, WI: Quest Products, Inc.; received June 2018.

American Academy of Pediatric Dentistry (AAPD). Guideline on infant oral health care. 2012. http://www.aapd.org/media/Policies_Guidelines/G_infantOralHealthCare.pdf.

American Academy of Pediatrics Oral Health Initiative (AAP). A Pediatric Guide to Children’s Oral Health. January, 2011. http://www2.aap.org/commpeds/dochs/oralhealth/docs/OralHealthFCpagesF2_2_1.pdf.

American Academy of Pediatrics Task Force on Circumcision. Male circumcision. Pediatrics. 2012;130:e756.

Anastia (lidocaine) [prescribing information]. Peoria, AZ: Solutech Pharmaceuticals LLC.; received September 2016.

Aspercreme (lidocaine) [prescribing information]. Chattanooga, TN: Chattam Inc; received March 2018.

Astero (lidocaine) [prescribing information]. Miami, FL: Gensco Laboratories, LLC; May 2016.

Cavalli Rde C, Lanchote VL, Duarte G, et al. Pharmacokinetics and Transplacental Transfer of Lidocaine and its Metabolite For Perineal Analgesic Assistance to Pregnant Women. Eur J Clin Pharmacol. 2004;60(8):569-574.[PubMed 15365654]

Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm[PubMed 6810084]

Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm.[PubMed 6423951]

Curtis LA, Dolan TS, and Seibert HE. Are one or two dangerous? Lidocaine and topical anesthetic exposures in children. J Emerg Med 2009;37(1):32-39.

Davies PS and Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs. 2004;64(9):937-947.[PubMed 15101784]

Dologesic (lidocaine) [prescribing information]. Miami, FL: Llorens Pharmaceutical International Division, Inc.; February 2018.

Dryden RM, Lo MW. Breast milk lidocaine levels in tumescent liposuction. Plast Reconstr Surg. 2000;105(6):2267-2268.[PubMed 10839430]

Eha lotion (lidocaine) [prescribing information]. Torrance, CA: Enovachem Pharmaceuticals; received September 2016.

Eichenfield LF, Funk A, Fallon-Friedlander S, Cunningham BB. A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anesthetics cream for pain reduction of venipuncture in children. Pediatrics. 2002;109(6):1093-1099.[PubMed 12042548]

Fein JA, Zempsky WT, Cravero JP; Committee on Pediatric Emergency Medicine and Section on Anesthesiology and Pain Medicine; American Academy of Pediatrics. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics. 2012;130(5):e1391-e1405.[PubMed 23109683]

Giard MJ, Uden DL, Whitlock DJ, and Watson DM. Seizures induced by oral viscous lidocaine. Clin Pharm. 1983;2(2):110.[PubMed 6883940]

Giuliani M, Grossi GB, Pileri M, Lajolo C, Casparrini G. Could local anesthesia while breast-feeding be harmful to infants? J Pediatr Gastroenterol Nutr. 2001;32(2):142-144.[PubMed 11321382]

Gonzalez del Rey J, Wason S, Druckenbrod RW. Lidocaine overdose: another preventable case? Pediatr Emerg Care. 1994;10(6):344-346.[PubMed 7899121]

Hess GP and Walson PD. Seizures secondary to oral viscous lidocaine. Ann Emerg Med. 1988;17(7):725-727.[PubMed 3382075]

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

Institute for Safe Medication Practice (ISMP), “Topical anesthetics for teething infants,” ISMP Medication Safety Alert, January 14, 2014. http://www.ismp.org/newsletters/acutecare/issues/20140116.pdf.

Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.[PubMed 12534540]

Koh JL, Harrison D, Myers R, Dembinski R, Turner H, McGraw T. A randomized, double-blind comparison study of EMAL and ELA-Max for topical anesthesia in children undergoing intravenous insertion. Paediatr Anesth. 2004;14(12):977-982.[PubMed 15601345]

Lebedevs TH, Wojnar-Horton RE, Yapp P, et al. Excretion of Lignocaine and its Metabolite Monoethylglycinexylidide in Breast Milk Following its Use in a Dental Procedure. A Case Report. J Clin Periodontol. 1993;20(8):606-608.[PubMed 8408724]

Lehr VT, Cepeda E, Frattarelli DA, et al, "Lidocaine 4% Cream Compared With Lidocaine 2.5% and Prilocaine 2.5% or Dorsal Penile Block for Circumcision," Am J Perinatol, 2005, 22(5):231-7.[PubMed 16041631]

Lidocaine 5% Ointment [prescribing information]. Memphis, TN: Northstar Rx LLC; October 2018.

Lidocaine hydrochloride 3% lotion [prescribing information]. Ocean Springs, MS: Alvix Laboratories; February 2015.

Lidocaine hydrochloride 4.12% cream [prescribing information]. San Fernando, CA: PharmaPure RX; April 2017.

Lidocaine hydrochloride gel [prescribing information]. Holland, OH: Quality Care Products, LLC; December 2016.

Lidocaine hydrochloride solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; August 2016.

Lidocaine hydrochloride topical solution [prescribing information]. Philadelphia, PA: Lannett Company, Inc; November 2019.

Lidocaine Viscous (lidocaine) [prescribing information]. Alpharetta, GA: Direct RX; October 2010.

Lidocaine Viscous 2% (lidocaine) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; September 2017.

Lidoderm (lidocaine patch 5%) [prescribing information]. Malvern, PA: Endo Pharmaceuticals; November 2018.

LidoDose (lidocaine hydrochloride 3%) topical anesthetic, single-use applicator [prescribing information]. Miami, FL: Gensco Pharma; November 2018.

Lido-K (lidocaine) [prescribing information]. Peoria, AZ: Solutech Pharmaceuticals; February 2018.

Lidopatch (lidocaine) [prescribing information]. Lake Forest, IL: JAR Laboratories; November 2017.

LiDORx (lidocaine) [prescribing information]. Miami, FL: Gensco Pharma, LLC; March 2017.

Lido-Rx 4.1 (lidocaine) [prescribing information]. Pensacola, FL: Cloverleaf Pharma, LLC; January 2016.

Lidotrex (lidocaine) [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals, LLC; March 2018.

Lidovex (lidocaine cream 3.75%) [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals; December 2014.

Lidovex (lidocaine cream) [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals, LLC; January 2015.

LMX4 cream (lidocaine) [prescribing information]. Ferndale, MI: Ferndale Laboratories, Inc; June 2014.

LMX5 cream (lidocaine) [prescribing information]. Ferndale, MI: Ferndale Laboratories, Inc; June 2014.

Luhmann J, Hurt S, Shootman M, Kennedy R. A comparison of buffered lidocaine versus ELA-Max before peripheral intravenous catheter insertions in children. Pediatrics. 2004;133(3 pt 1):e217-e220.[PubMed 14993579]

Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172.[PubMed 10985636]

Mitani GM, Steinberg I, Lien EJ, et al. The Pharmacokinetics of Antiarrhythmic Agents in Pregnancy and Lactation. Clin Pharmacokinet. 1987;12(4):253-291.[PubMed 3297463]

Mofenson HC, Caraccio TR, Miller H, Greensher J. Lidocaine toxicity from topical mucosal application. With a review of the clinical pharmacology of lidocaine. Clin Pediatr (Phila). 1983;22(3):190-192.[PubMed 6825363]

Ortega D, Viviand X, Lorec AM, et al. Excretion of Lidocaine and Bupivacaine in Breast Milk Following Epidural Anesthesia for Cesarean Delivery. Acta Anaesthesiol Scand. 1999;43(4):394-397.[PubMed 10225071]

Puczynski MS, Ow EP, and Rust C. Cardiopulmonary arrest due to misuse of viscous lidocaine. Arch Otolaryngol. 1985;111(11):768-769.[PubMed 4051869]

Rothstein P, Dornbusch J, Shaywitz BA. Prolonged seizures associated with the use of viscous lidocaine. J Pediatr. 101(3):461-463.[PubMed 7108671]

Sakai RI, Lattin JE. Lidocaine ingestion. Am J Dis Child. 1980;1344(3):323.[PubMed 7361745]

Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259.[PubMed 19188870]

Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.[PubMed 7746084]

Smith M, Wolfram W, Rose R. Toxicity- seizures in an infant caused by (or related to) oral viscous lidocaine use. J Emerg Med. 1992;10(5):587-590.[PubMed 1401862]

Sobanko JF, Miller CJ, Alster TS. Topical anesthetics for dermatologic procedures: a review. Dermatol Surg. 2012;38(5):709-721.[PubMed 22243434 ]

Taddio A, Soin HK, Schuh S, Koren G, Scolnik D. Liposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trial. CMAJ. 2005;172(13):1691-1695.[PubMed 15967972]

Topicaine (lidocaine) [prescribing information]. Jupiter Park, FL: Esba Laboratories, Inc; June 2015.

Tranzarel (lidocaine) [prescribing information]. Eatontown, NJ: Taleos Pharma Corp.; August 2017.

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/

Xylocaine 2% jelly (lidocaine hydrochloride) [prescribing information]. Lake Forest, IL: Akorn, Inc.; June 2012.

Xylocaine Endotracheal (lidocaine non-aerosol spray) [package insert]. Toronto, Ontario, Canada; Aspen Pharmacare Canada Inc: April 2017.

Xylocaine Viscous 2% (lidocaine hydrochloride) [prescribing information]. Lake Zurich, IL; Fresenius Kalbi USA, LLC: September 2014.

Zeisler JA, Gaarder TD, De Mesquita SA. Lidocaine excretion in breast milk. Drug Intell Clin Pharm. 1986;20(9):691-693.[PubMed 3757781]

Zingo (lidocaine) [prescribing information]. Las Vegas, NV: 7T Pharma LLC; November 2018.

Zionodil (lidocaine) [prescirbing information]. Las Vegas, NV: Bodysphere, LLC; received December 2019.

ZTlido (lidocaine) [prescribing information]. San Diego, CA: Scilex Pharmaceuticals Inc; November 2018.

Brand Names: International

Akten (LB); Chalocaine Jelly (TH); Dermomax (BR); Dimecaina (CL); Dynexan (CH, FR); Esracain Jelly (IL); Gesicain Jelly (IN); Gesicain Ointment (IN); Gesicain Viscous (IN); Happycain (KR); Kenergon (CH); Lambdalina (ES); Lecasin (KR); Leostesin Jelly (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Leostesin Ointment (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW); Lidocain Gel (FI); Lidocain Spray (BG); Lidoderm (GR); Lidopain (BD); Lidotop Cataplasma (KR); Lignocaine Gel (AU); Lignopad (HK, MY); Peterkaien (ZA); Pisacaina (EC); Power Gel (KR); Prolong 1000 (CL, PE); Rialocaine (QA); Rocky Gel (KR); Roxicaina (CO); Solarcaine (HK); Stud 100 (AU, IL, MT); Versatis (BE, CL, CO, EC, EE, ES, HR, HU, LT, LU, LV, MT, PE, RO, RU, SE, SK, UA); Versatis Plaster (GB, IE); Xilonest (PE); Xilotane Oral (PT); Xylocain (IS); Xylocain Aerosol (DK, SE); Xylocain Gel (AT, CH, DE, DK, FI, NO, SE); Xylocain Liniment (DK); Xylocain Ointment (AT, CH, DE, FI); Xylocain Salve (DK); Xylocain Spray (AT, CH, DE, NO); Xylocain Viscous (AT, CH); Xylocain Viskos (DE, SE); Xylocain Visks (FI); Xylocaina Ointment (IT); Xylocaina Pomada (AR); Xylocaina Spray (CO, IT); Xylocaine (LK, SI); Xylocaine Aerosol (AU, HK, NL); Xylocaine Gel (AE, BE, BH, CY, EG, FR, GR, IE, IQ, IR, JO, KW, LB, LY, OM, PK, QA, SA, SY, YE); Xylocaine Jalea (UY); Xylocaine Jelly (BF, BJ, CI, ET, GH, GM, GN, HK, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, NZ, PH, SC, SD, SG, SL, SN, TH, TN, TW, TZ, UG, VN, ZM, ZW); Xylocaine Ointment (AE, AU, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, IN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, PH, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW); Xylocaine Pump Spray (AU, EE); Xylocaine Spray (BE, BF, BJ, CI, ET, GB, GH, GM, GN, GR, HK, IL, KE, KR, LI, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, PH, PL, SC, SD, SG, SL, SN, TH, TN, TW, TZ, UG, ZA, ZM, ZW); Xylocaine Topical Solution (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Xylocaine Viscosa (PY); Xylocaine Viscous (GB, IE, IN, MY, TH); Xylocaine Viscous Topical Solution (AU, GB); Xylocaine Viscus (GR); Xylocaine Viskeus Topical Solution (NL); Xylone (BD); Ziagel (AU)

Last Updated 3/25/20